Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?

समान संसाधन

• Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms
  द्वारा: Raucci, Federica, और अन्य
  प्रकाशित: (2020)
• In-depth immunophenotyping data relating to IL-17Ab modulation of circulating Treg/Th17 cells and of in situ infiltrated inflammatory monocytes in the onset of gouty inflammation
  द्वारा: Raucci, Federica, और अन्य
  प्रकाशित: (2019)
• Present Status and Future Trends of Natural-Derived Compounds Targeting T Helper (Th) 17 and Microsomal Prostaglandin E Synthase-1 (mPGES-1) as Alternative Therapies for Autoimmune and Inflammatory-Based Diseases
  द्वारा: Saviano, Anella, और अन्य
  प्रकाशित: (2020)
• Repetitive Exposure of IL-17 Into the Murine Air Pouch Favors the Recruitment of Inflammatory Monocytes and the Release of IL-16 and TREM-1 in the Inflammatory Fluids
  द्वारा: Maione, Francesco, और अन्य
  प्रकाशित: (2018)
• Interleukin-17A (IL-17A): A silent amplifier of COVID-19
  द्वारा: Maione, Francesco, और अन्य
  प्रकाशित: (2021)